Head-to-head evidence
GlyphAllo (allopregnanolone prodrug) vs HS-10353
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: GABA-A receptor · full Major Depressive Disorder pipeline
GlyphAllo (allopregnanolone prodrug) · SPT-300
Developed by PureTech Health and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07065240 (registry estimate)
HS-10353
Developed by Hansoh Pharmaceutical Group
NCT05195203 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GlyphAllo (allopregnanolone prodrug)'s landscape · HS-10353's landscape